Analysts expect Elanco Animal Health to report Q3 2026 revenue of approximately $1.21 billion and adjusted EPS of $0.20, with the stock currently trading near $25.20 relative to a $30.23 average price target.
Investors are primarily focused on the commercial adoption of the company's "Big 6" innovation products, specifically the blockbuster launches of Zenrelia and Credelio Quattro, which are key to capturing market share in the dermatology and parasiticide categories.
Recent performance has been bolstered by an 8% organic constant currency revenue growth in the previous quarter, driven by high demand in the U.S. Pet Health segment.
Management's focus remains on deleveraging, with plans to reduce net leverage below 3x by 2027 as profitability expands from new product margins.